Abstract
Many epidemiologic studies have investigated the association between myeloperoxidase (MPO) G-463A polymorphism and lung cancer risk, but the results were controversial. We performed a meta-analysis of 25 studies on MPO polymorphism and lung cancer risk published before July 2013. The allele of A was found to be associated with decreased risk of lung cancer compared with G allele (OR, 0.90; 95 % CI, 0.82–0.98) in the general population. The significant association remained in the comparison between AA + AG and GG (OR, 0.92; 95 % CI, 0.87–0.98). When it was stratified according to Asian population, the association between MPO polymorphism and lung cancer risk was further strengthened. However, no associations were found in the Caucasian population. This meta-analysis has demonstrated that MPO polymorphism might contribute to individual’s susceptibility to lung cancer in Asian population. Caucasian authors could re-investigate the association between MPO polymorphism and lung cancer risk with more specific participants. Future studies focusing on interactions between combined genes and environmental risk factors are warranted.
Similar content being viewed by others
References
Lee PN. Relation between exposure to asbestos and smoking jointly and the risk of lung cancer. Occup Environ Med. 2001;58:145–53.
Alberg AJ, Ford JG, Samet JM, American College of Chest Physicians. Epidemiology of lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). Chest. 2007;132:29S–55S.
Marshall AL, Christiani DC. Genetic susceptibility to lung cancer—light at the end of the tunnel? Carcinogenesis. 2013;34:487–502.
Klebanoff SJ. Myeloperoxidase: friend and foe. J Leukoc Biol. 2005;77:598–625.
Cascorbi I, Henning S, Brockmoller J, Gephart J, Meisel C, Muller JM, et al. Substantially reduced risk of cancer of the aerodigestive tract in subjects with variant—463a of the myeloperoxidase gene. Cancer Res. 2000;60:644–9.
Kiyohara C, Yoshimasu K, Takayama K, Nakanishi Y. Nqo1, mpo, and the risk of lung cancer: a huge review. Genet Med. 2005;7:463–78.
Taioli E, Benhamou S, Bouchardy C, Cascorbi I, Cajas-Salazar N, Dally H, et al. Myeloperoxidase g-463a polymorphism and lung cancer: a huge genetic susceptibility to environmental carcinogens pooled analysis. Genet Med. 2007;9:67–73.
Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557–60.
Lu W, Xing D, Qi J, Tan W, Miao X, Lin D. Genetic polymorphism in myeloperoxidase but not gstm1 is associated with risk of lung squamous cell carcinoma in a Chinese population. Int J Cancer. 2002;102:275–9.
Wu XM, Zhou YK, Ren S. Hao QL: [gene polymorphism of myeloperoxidase and genetic susceptibility to lung cancer]. Ai Zheng. 2003;22:912–5.
Chan EC, Lam SY, Fu KH, Kwong YL. Polymorphisms of the gstm1, gstp1, mpo, xrcc1, and nqo1 genes in Chinese patients with non-small cell lung cancers: relationship with aberrant promoter methylation of the cdkn2a and rarb genes. Cancer Genet Cytogenet. 2005;162:10–20.
Park JH, Park JM, Kim EJ, Cha SI, Lee EB, Kim CH, et al. Myeloperoxidase-463g > a polymorphism and risk of primary lung cancer in a Korean population. Cancer Detect Prev. 2006;30:257–61.
Zhang T, Hong X, Wu Y, Wu Y. Myeloperoxidase polymorphism in lung cancer patients of Henan Han population. Journal of Zhengzhou University. 2007;42:448–50.
Yang M, Choi Y, Hwangbo B, Lee JS. Combined effects of genetic polymorphisms in six selected genes on lung cancer susceptibility. Lung Cancer. 2007;57:135–42.
Yoon KA, Kim JH, Gil HJ, Hwang H, Hwangbo B, Lee JS. Cyp1b1, cyp1a1, mpo, and gstp1 polymorphisms and lung cancer risk in never-smoking korean women. Lung Cancer. 2008;60:40–6.
Schabath MB, Spitz MR, Zhang X, Delclos GL, Wu X. Genetic variants of myeloperoxidase and lung cancer risk. Carcinogenesis. 2000;21:1163–6.
Xu LL, Liu G, Miller DP, Zhou W, Lynch TJ, Wain JC, et al. Counterpoint: the myeloperoxidase-463g—a polymorphism does not decrease lung cancer susceptibility in Caucasians. Cancer Epidemiol Biomarkers Prev. 2002;11:1555–9.
Feyler A, Voho A, Bouchardy C, Kuokkanen K, Dayer P, Hirvonen A, et al. Point: myeloperoxidase-463g—a polymorphism and lung cancer risk. Cancer Epidemiol Biomarkers Prev. 2002;11:1550–4.
Dally H, Gassner K, Jager B, Schmezer P, Spiegelhalder B, Edler L, et al. Myeloperoxidase (mpo) genotype and lung cancer histologic types: the mpo-463 a allele is associated with reduced risk for small cell lung cancer in smokers. Int J Cancer. 2002;102:530–5.
Schabath MB, Spitz MR, Delclos GL, Gunn GB, Whitehead LW, Wu X. Association between asbestos exposure, cigarette smoking, myeloperoxidase (mpo) genotypes, and lung cancer risk. Am J Ind Med. 2002;42:29–37.
Kantarci OH, Lesnick TG, Yang P, Meyer RL, Hebrink DD, McMurray CT, et al. Myeloperoxidase-463 (g–a) polymorphism associated with lower risk of lung cancer. Mayo Clin Proc. 2002;77:17–22.
Misra RR, Tangrea JA, Virtamo J, Ratnasinghe D, Andersen MR, Barrett M, et al. Variation in the promoter region of the myeloperoxidase gene is not directly related to lung cancer risk among male smokers in Finland. Cancer Lett. 2001;164:161–7.
Chevrier I, Stucker I, Houllier AM, Cenee S, Beaune P, Laurent-Puig P, et al. Myeloperoxidase: new polymorphisms and relation with lung cancer risk. Pharmacogenetics. 2003;13:729–39.
Cajas-Salazar N, Sierra-Torres CH, Salama SA, Zwischenberger JB, Au WW. Combined effect of mpo, gstm1 and gstt1 polymorphisms on chromosome aberrations and lung cancer risk. Int J Hyg Environ Health. 2003;206:473–83.
Liu G, Zhou W, Wang LI, Park S, Miller DP, Xu LL, et al. Mpo and sod2 polymorphisms, gender, and the risk of non-small cell lung carcinoma. Cancer Lett. 2004;214:69–79.
Harms C, Salama SA, Sierra-Torres CH, Cajas-Salazar N, Au WW. Polymorphisms in DNA repair genes, chromosome aberrations, and lung cancer. Environ Mol Mutagen. 2004;44:74–82.
Larsen JE, Colosimo ML, Yang IA, Bowman R, Zimmerman PV, Fong KM. Cyp1a1 ile462val and mpo g-463a interact to increase risk of adenocarcinoma but not squamous cell carcinoma of the lung. Carcinogenesis. 2006;27:525–32.
Zienolddiny S, Campa D, Lind H, Ryberg D, Skaug V, Stangeland LB, et al. A comprehensive analysis of phase i and phase ii metabolism gene polymorphisms and risk of non-small cell lung cancer in smokers. Carcinogenesis. 2008;29:1164–9.
Rotunno M, Yu K, Lubin JH, Consonni D, Pesatori AC, Goldstein AM, et al. Phase i metabolic genes and risk of lung cancer: multiple polymorphisms and mrna expression. PLoS One. 2009;4:e5652.
Arslan S, Pinarbasi H, Silig Y. Myeloperoxidase g-463a polymorphism and risk of lung and prostate cancer in a Turkish population. Mol Med Rep. 2011;4:87–92.
London SJ, Lehman TA, Taylor JA. Myeloperoxidase genetic polymorphism and lung cancer risk. Cancer Res. 1997;57:5001–3.
Le Marchand L, Seifried A, Lum A, Wilkens LR. Association of the myeloperoxidase -463g–a polymorphism with lung cancer risk. Cancer Epidemiol Biomarkers Prev. 2000;9:181–4.
Mattson ME, Pollack ES, Cullen JW. What are the odds that smoking will kill you? Am J Public Health. 1987;77:425–31.
Peto R, Darby S, Deo H, Silcocks P, Whitley E, Doll R. Smoking, smoking cessation, and lung cancer in the UK since 1950: combination of national statistics with two case–control studies. BMJ. 2000;321:323–9.
Doll R, Peto R. The causes of cancer: quantitative estimates of avoidable risks of cancer in the United States today. J Natl Cancer Inst. 1981;66:1191–308.
Schwartz AG, Prysak GM, Bock CH, Cote ML. The molecular epidemiology of lung cancer. Carcinogenesis. 2007;28:507–18.
Landi MT, Chatterjee N, Yu K, Goldin LR, Goldstein AM, Rotunno M, et al. A genome-wide association study of lung cancer identifies a region of chromosome 5p15 associated with risk for adenocarcinoma. Am J Hum Genet. 2009;85:679–91.
Ito H, McKay JD, Hosono S, Hida T, Yatabe Y, Mitsudomi T, et al. Association between a genome-wide association study-identified locus and the risk of lung cancer in Japanese population. J Thorac Oncol. 2012;7:790–8.
de Mello RA, Ferreira M, Costa S, Costa BM, Pires FS, Neves I, et al. Association between egf +61 genetic polymorphisms and non-small cell lung cancer increased risk in a Portuguese population: a case–control study. Tumour Biol. 2012;33:1341–8.
Conflicts of interest
None
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Huang, C., Ma, L. & Li, D. Association between myeloperoxidase G-463A polymorphism and lung cancer risk. Tumor Biol. 35, 475–481 (2014). https://doi.org/10.1007/s13277-013-1067-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13277-013-1067-6